Trials / Completed
CompletedNCT00426530
Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
A Phase Ib Study Investigating the Combination of Everolimus With Trastuzumab and Vinorelbine in Patients With HER2-overexpressing Metastatic Breast Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will look at different dose levels and regimens of everolimus combined with weekly trastuzumab and vinorelbine therapy in patients with HER-2 overexpressing metastatic breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | everolimus (RAD001) |
Timeline
- Start date
- 2007-02-01
- Primary completion
- 2010-06-01
- Completion
- 2010-06-01
- First posted
- 2007-01-24
- Last updated
- 2020-12-21
Locations
6 sites across 5 countries: Belgium, France, Italy, Poland, Sweden
Source: ClinicalTrials.gov record NCT00426530. Inclusion in this directory is not an endorsement.